Oxford Molecular Execs Consider Sale of Company, GCG’s Devereux Retires | GenomeWeb


XFORD, UK--Executives at Oxford Molecular have acknowledged that they and their advisors, Donaldson Lufkin & Jenrette International, are considering a sale of the company. The company last month announced 1999 losses of £26 million and plans to cut 55 jobs.

James Hiddleston, a company director here, told BioInform that Oxford Molecular’s bioinformatics business has been expanding and that a new strategy calls for concentrating resources on development of drug discovery software.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.